{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:30Z","timestamp":1792787970774,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Clinical Key Specialty Construction Project of Cardiovascular Medicine at Chuxiong People's Hospital","award":["No.: 2024ZK01"],"award-info":[{"award-number":["No.: 2024ZK01"]}],"id":[{"id":"https:\/\/ror.org\/00syn8y15","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Research Project of Chuxiong Medical College","award":["No.: 2021YYXM01"],"award-info":[{"award-number":["No.: 2021YYXM01"]}],"id":[{"id":"https:\/\/ror.org\/01e6nkr19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Training Program for Middle-aged and Young Backbone Physicians in Yunnan Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04424-x","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:04:11Z","timestamp":1784693051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bladder cancer organoids in precision medicine: bridging basic science, clinical therapeutics and drug development"],"prefix":"10.1186","volume":"26","author":[{"given":"Xuesong","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5022-2239","authenticated-orcid":false,"given":"Jian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"4424_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4424_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020;324:1980\u201391.","journal-title":"JAMA"},{"key":"4424_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104\u201321.","journal-title":"Nat Rev Cancer"},{"key":"4424_CR4","first-page":"11536","volume":"24","author":"G Facchini","year":"2020","unstructured":"Facchini G, Cavaliere C, Romis L, Mordente S, Facchini S, Iovane G, et al. Advanced\/metastatic bladder cancer: current status and future directions. Eur Rev Med Pharmacol Sci. 2020;24:11536\u201352.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4424_CR5","doi-asserted-by":"crossref","unstructured":"Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17:259\u201370.","DOI":"10.1038\/s41585-020-0304-1"},{"key":"4424_CR6","doi-asserted-by":"publisher","first-page":"5293","DOI":"10.7150\/ijbs.96469","volume":"20","author":"A Esposito","year":"2024","unstructured":"Esposito A, Ferraresi A, Vallino L, Garavaglia B, Dhanasekaran DN, Isidoro C. Three-dimensional in vitro cell cultures as a feasible and promising alternative to two-dimensional and animal models in cancer research. Int J Biol Sci. 2024;20:5293\u2013311.","journal-title":"Int J Biol Sci"},{"key":"4424_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-019-0832-4","volume":"12","author":"H Fan","year":"2019","unstructured":"Fan H, Demirci U, Chen P. Emerging organoid models: leaping forward in cancer research. J Hematol Oncol. 2019;12:142.","journal-title":"J Hematol Oncol"},{"key":"4424_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.euf.2022.07.006","volume":"8","author":"YS Kim","year":"2022","unstructured":"Kim YS, Hsieh AC, Lam HM. Bladder cancer patient-derived organoids and avatars for personalized cancer discovery. Eur Urol Focus. 2022;8:657\u20139.","journal-title":"Eur Urol Focus"},{"key":"4424_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318.","journal-title":"Nat Rev Cancer"},{"key":"4424_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173:515\u201328.","journal-title":"Cell"},{"key":"4424_CR11","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","volume":"14","author":"M Minoli","year":"2023","unstructured":"Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, et al. Bladder cancer organoids as a functional system to model different disease stages and therapy response. Nat Commun. 2023;14:2214.","journal-title":"Nat Commun"},{"key":"4424_CR12","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.7150\/thno.96027","volume":"14","author":"D Xiang","year":"2024","unstructured":"Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T, et al. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development. Theranostics. 2024;14:3300\u201316.","journal-title":"Theranostics"},{"key":"4424_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100840","volume":"13","author":"C Liu","year":"2020","unstructured":"Liu C, Qin T, Huang Y, Li Y, Chen G, Sun C. Drug screening model meets cancer organoid technology. Transl Oncol. 2020;13:100840.","journal-title":"Transl Oncol"},{"key":"4424_CR14","doi-asserted-by":"publisher","first-page":"e006290","DOI":"10.1136\/jitc-2022-006290","volume":"11","author":"L Magr\u00e9","year":"2023","unstructured":"Magr\u00e9 L, Verstegen MMA, Buschow S, van der Laan LJW, Peppelenbosch M, Desai J. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies. J Immunother Cancer. 2023;11:e006290.","journal-title":"J Immunother Cancer"},{"key":"4424_CR15","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017;28:2595\u2013605.","journal-title":"Ann Oncol"},{"key":"4424_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/2159-8290.CD-17-0935","volume":"8","author":"BJ Drapkin","year":"2018","unstructured":"Drapkin BJ, George J, Christensen CL, Mino-Kenudson M, Dries R, Sundaresan T, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts. Cancer Discov. 2018;8:600\u201315.","journal-title":"Cancer Discov"},{"key":"4424_CR17","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ng.3967","volume":"49","author":"U Ben-David","year":"2017","unstructured":"Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49:1567\u201375.","journal-title":"Nat Genet"},{"key":"4424_CR18","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1073\/pnas.1803595116","volume":"116","author":"J Mullenders","year":"2019","unstructured":"Mullenders J, de Jongh E, Brousali A, Roosen M, Blom JPA, Begthel H, et al. Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci U S A. 2019;116:4567\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4424_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462\u201377.","journal-title":"Cancer Discov"},{"key":"4424_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172188","volume":"12","author":"S Walz","year":"2023","unstructured":"Walz S, Pollehne P, Geng R, Schneider J, Maas M, Aicher WK, et al. A protocol for organoids from the urine of bladder cancer patients. Cells. 2023;12:2188.","journal-title":"Cells"},{"key":"4424_CR21","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","volume":"175","author":"JT Neal","year":"2018","unstructured":"Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175:1972\u2013e8816.","journal-title":"Cell"},{"key":"4424_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-020-3034-x","volume":"588","author":"E Kim","year":"2020","unstructured":"Kim E, Choi S, Kang B, Kong J, Kim Y, Yoon WH, et al. Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature. 2020;588:664\u20139.","journal-title":"Nature"},{"issue":"3","key":"4424_CR23","doi-asserted-by":"publisher","first-page":"035030","DOI":"10.1088\/1758-5090\/ab9491","volume":"12","author":"WH Yoon","year":"2020","unstructured":"Yoon WH, Lee HR, Kim S, Kim E, Ku JH, Shin K, et al. Use of inkjet-printed single cells to quantify intratumoral heterogeneity. Biofabrication. 2020;12:035030.","journal-title":"Biofabrication"},{"key":"4424_CR24","doi-asserted-by":"publisher","first-page":"e1248","DOI":"10.1002\/cti2.1248","volume":"10","author":"L Yu","year":"2021","unstructured":"Yu L, Li Z, Mei H, Li W, Chen D, Liu L, et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin Transl Immunol. 2021;10:e1248.","journal-title":"Clin Transl Immunol"},{"key":"4424_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.omto.2022.01.009","volume":"24","author":"C Rangsitratkul","year":"2022","unstructured":"Rangsitratkul C, Lawson C, Bernier-Godon F, Niavarani SR, Boudaud M, Rouleau S, et al. Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer. Mol Ther Oncolytics. 2022;24:507\u201321.","journal-title":"Mol Ther Oncolytics"},{"key":"4424_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41698-023-00466-w","volume":"7","author":"M Garioni","year":"2023","unstructured":"Garioni M, Tschan VJ, Blukacz L, Nuciforo S, Parmentier R, Roma L, et al. Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer. NPJ Precis Oncol. 2023;7:112.","journal-title":"NPJ Precis Oncol"},{"key":"4424_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","volume":"130","author":"BJ Viergever","year":"2024","unstructured":"Viergever BJ, Raats DAE, Geurts V, Mullenders J, Jonges TN, van der Heijden MS, et al. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation. Br J Cancer. 2024;130:369\u201379.","journal-title":"Br J Cancer"},{"key":"4424_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202414558","volume":"12","author":"H Zhao","year":"2025","unstructured":"Zhao H, Lin N, Ho VWS, Liu K, Chen X, Wu H, et al. Patient-derived bladder cancer organoids as a valuable tool for understanding tumor biology and developing personalized treatment. Adv Sci (Weinh). 2025;12:e2414558.","journal-title":"Adv Sci (Weinh)"},{"key":"4424_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2021.01.025","volume":"504","author":"S Kaur","year":"2021","unstructured":"Kaur S, Kaur I, Rawal P, Tripathi DM, Vasudevan A. Non-matrigel scaffolds for organoid cultures. Cancer Lett. 2021;504:58\u201366.","journal-title":"Cancer Lett"},{"key":"4424_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202317613","volume":"63","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Zhang S, Jiang N, Zhu W, Song D, Liu S, et al. Patient-derived immunocompetent tumor organoids: a platform for chemotherapy evaluation in the context of T-cell recognition. Angew Chem Int Ed Engl. 2024;63:e202317613.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4424_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1088\/1758-5090\/ad51a6","volume":"16","author":"R Dai","year":"2024","unstructured":"Dai R, Chen W, Chen Y, Jin J, Zhang S, Zhang C, et al. 3D bioprinting platform development for high-throughput cancer organoid models construction and drug evaluation. Biofabrication. 2024;16:1\u201337.","journal-title":"Biofabrication"},{"key":"4424_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540\u201356.","journal-title":"Cell"},{"key":"4424_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14256-0","volume":"12","author":"JM Vlaar","year":"2022","unstructured":"Vlaar JM, Borgman A, Kalkhoven E, Westland D, Besselink N, Shale C, et al. Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer. Sci Rep. 2022;12:10081.","journal-title":"Sci Rep"},{"key":"4424_CR34","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.7150\/ijbs.74546","volume":"18","author":"L Shen","year":"2022","unstructured":"Shen L, Zhang J, Zheng Z, Yang F, Liu S, Wu Y, et al. PHGDH inhibits ferroptosis and promotes malignant progression by upregulating SLC7A11 in bladder cancer. Int J Biol Sci. 2022;18:5459\u201374.","journal-title":"Int J Biol Sci"},{"key":"4424_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41419-023-05661-y","volume":"14","author":"N Wang","year":"2023","unstructured":"Wang N, Chen RX, Deng MH, Wei WS, Zhou ZH, Ning K, et al. m5C-dependent cross-regulation between nuclear reader ALYREF and writer NSUN2 promotes urothelial bladder cancer malignancy through facilitating RABL6\/TK1 mRNAs splicing and stabilization. Cell Death Dis. 2023;14:139.","journal-title":"Cell Death Dis"},{"key":"4424_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105453","volume":"23","author":"R Geng","year":"2022","unstructured":"Geng R, Harland N, Montes-Mojarro IA, Fend F, Aicher WK, Stenzl A, et al. CD24: a marker for an extended expansion potential of urothelial cancer cell organoids in vitro? Int J Mol Sci. 2022;23:5453.","journal-title":"Int J Mol Sci"},{"key":"4424_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41419-023-05938-2","volume":"14","author":"K Xiao","year":"2023","unstructured":"Xiao K, Peng S, Lu J, Zhou T, Hong X, Chen S, et al. UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer. Cell Death Dis. 2023;14:408.","journal-title":"Cell Death Dis"},{"key":"4424_CR38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ccell.2022.08.010","volume":"40","author":"M Wang","year":"2022","unstructured":"Wang M, Chen X, Tan P, Wang Y, Pan X, Lin T, et al. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell. 2022;40:1044\u2013e10598.","journal-title":"Cancer Cell"},{"key":"4424_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217793","volume":"625","author":"R Yang","year":"2025","unstructured":"Yang R, Wang S, Li Z, Yin C, Huang W, Huang W. Patient-derived organoid co-culture systems as next-generation models for bladder cancer stem cell research. Cancer Lett. 2025;625:217793.","journal-title":"Cancer Lett"},{"key":"4424_CR40","doi-asserted-by":"publisher","first-page":"e2101312","DOI":"10.1002\/adhm.202101312","volume":"10","author":"Z Gong","year":"2021","unstructured":"Gong Z, Huang L, Tang X, Chen K, Wu Z, Zhang L, et al. Acoustic Droplet Printing Tumor Organoids for Modeling Bladder Tumor Immune Microenvironment within a Week. Adv Healthc Mater. 2021;10:e2101312.","journal-title":"Adv Healthc Mater"},{"key":"4424_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","volume":"16","author":"ME Shaul","year":"2019","unstructured":"Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16:601\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"4424_CR42","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-023-02552-z","volume":"130","author":"Y Ouyang","year":"2024","unstructured":"Ouyang Y, Zhong W, Xu P, Wang B, Zhang L, Yang M, et al. Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2\/PGE2\/IDO1 Axis. Br J Cancer. 2024;130:880\u201391.","journal-title":"Br J Cancer"},{"key":"4424_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249\u201357.","journal-title":"Nature"},{"key":"4424_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298\u2013307.","journal-title":"Nature"},{"key":"4424_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10555-007-9084-9","volume":"26","author":"PC Black","year":"2007","unstructured":"Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev. 2007;26:623\u201334.","journal-title":"Cancer Metastasis Rev"},{"key":"4424_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202412815","volume":"37","author":"Y Du","year":"2025","unstructured":"Du Y, Wang YR, Bao QY, Xu XX, Xu C, Wang S, et al. Personalized vascularized tumor organoid-on-a-chip for tumor metastasis and therapeutic targeting assessment. Adv Mater. 2025;37:e2412815.","journal-title":"Adv Mater"},{"key":"4424_CR47","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/acef99","volume":"15","author":"S Kim","year":"2023","unstructured":"Kim S, Park J, Ho JN, Kim D, Lee S, Jeon JS. 3D vascularized microphysiological system for investigation of tumor-endothelial crosstalk in anti-cancer drug resistance. Biofabrication. 2023;15:045016.","journal-title":"Biofabrication"},{"key":"4424_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43556-023-00165-9","volume":"5","author":"S Qu","year":"2024","unstructured":"Qu S, Xu R, Yi G, Li Z, Zhang H, Qi S, et al. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine. Mol Biomed. 2024;5:6.","journal-title":"Mol Biomed"},{"key":"4424_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/23523735251330404","volume":"11","author":"H Zhao","year":"2025","unstructured":"Zhao H, Ho VWS, Liu K, Chen X, Wu H, Chiu PK, et al. Organoid models in bladder cancer: from bench to bedside? Bladder Cancer. 2025;11:23523735251330404.","journal-title":"Bladder Cancer"},{"key":"4424_CR50","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.3390\/ijms23116305","volume":"23","author":"Y Wei","year":"2022","unstructured":"Wei Y, Amend B, Todenh\u00f6fer T, Lipke N, Aicher WK, Fend F, et al. Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems. Int J Mol Sci. 2022;23:6305.","journal-title":"Int J Mol Sci"},{"key":"4424_CR51","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920\u20136.","journal-title":"Science"},{"key":"4424_CR52","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.eururo.2006.10.034","volume":"51","author":"JP Burgu\u00e9s","year":"2007","unstructured":"Burgu\u00e9s JP, G\u00f3mez L, Pontones JL, Vera CD, Jim\u00e9nez-Cruz JF, Ozonas M. A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur Urol. 2007;51:962\u20139. discussion 969\u2009\u2013\u200970.","journal-title":"Eur Urol"},{"key":"4424_CR53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735\u201347.","journal-title":"Cancer Cell"},{"key":"4424_CR54","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457\u201361.","journal-title":"Science"},{"key":"4424_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/15384047.2021.1919004","volume":"22","author":"M Elbadawy","year":"2021","unstructured":"Elbadawy M, Sato Y, Mori T, Goto Y, Hayashi K, Yamanaka M, et al. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. Cancer Biol Ther. 2021;22:357\u201371.","journal-title":"Cancer Biol Ther"},{"key":"4424_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijpharm.2017.07.084","volume":"531","author":"P Roy","year":"2017","unstructured":"Roy P, Canet-Jourdan C, Annereau M, Zajac O, Gelli M, Broutin S, et al. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: preclinical models to improve HIPEC. Int J Pharm. 2017;531:143\u201352.","journal-title":"Int J Pharm"},{"key":"4424_CR57","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40487-025-00411-w","volume":"14","author":"S Sagliocchi","year":"2026","unstructured":"Sagliocchi S, Musone M, Chianese S, Cicatiello AG, Del Mastro S, Del Giudice F, et al. Toward personalized treatment of urogenital cancers: the role of patient-derived organoids. Oncol Ther. 2026;14:155\u201371.","journal-title":"Oncol Ther"},{"key":"4424_CR58","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.jlb.2025.100454","volume":"11","author":"A Nappi","year":"2026","unstructured":"Nappi A, Crocetto F, Conforti P, Sagliocchi S, Cicatiello AG, Restolfer F, et al. Cell-free RNA profiling uncovers non-canonical circulating D2 transcript elevation in Bladder Cancer plasma. J Liq Biopsy. 2026;11:100454.","journal-title":"J Liq Biopsy"},{"key":"4424_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1080273","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Wu C, Zhang S, Yu P, Li L, Guo C, et al. A novel deep learning segmentation model for organoid-based drug screening. Front Pharmacol. 2022;13:1080273. https:\/\/doi.org\/10.3389\/fphar.2022.1080273.","journal-title":"Front Pharmacol"},{"key":"4424_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1064548","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang S, Li L, Yu P, Wu C, Wang X, Liu M, et al. A deep learning model for drug screening and evaluation in bladder cancer organoids. Front Oncol. 2023;13:1064548. https:\/\/doi.org\/10.3389\/fonc.2023.1064548.","journal-title":"Front Oncol"},{"key":"4424_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19313-8","volume":"11","author":"J Kong","year":"2020","unstructured":"Kong J, Lee H, Kim D, Han SK, Ha D, Shin K, et al. Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. Nat Commun. 2020;11:5485. https:\/\/doi.org\/10.1038\/s41467-020-19313-8.","journal-title":"Nat Commun"},{"key":"4424_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01082-6","volume":"9","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Dai Q, Xu Y, Wu S, Cheng M, Zhao B. PharmaFormer predicts clinical drug responses through transfer learning guided by patient derived organoid. NPJ Precis Oncol. 2025;9:282. https:\/\/doi.org\/10.1038\/s41698-025-01082-6.","journal-title":"NPJ Precis Oncol"},{"key":"4424_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136956","volume":"23","author":"L Becker","year":"2022","unstructured":"Becker L, Fischer F, Fleck JL, Harland N, Herkommer A, Stenzl A, et al. Data-driven identification of biomarkers for in situ monitoring of drug treatment in bladder cancer organoids. Int J Mol Sci. 2022;23:6956. https:\/\/doi.org\/10.3390\/ijms23136956.","journal-title":"Int J Mol Sci"},{"key":"4424_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.71052\/srb2024\/GOUI6134","volume":"3","author":"HW Peng","year":"2026","unstructured":"Peng HW, Shang J, Qian KY, Zou C, Shi JG, Zhou ZN, et al. Artificial Intelligence-Assisted Phenotypic Analysis of Bladder Cancer Organoids: Toward Digital Precision Oncology. Sci Res Bull. 2026;3:34\u201341. https:\/\/doi.org\/10.71052\/srb2024\/GOUI6134.","journal-title":"Sci Res Bull"},{"key":"4424_CR65","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813\u201323.","journal-title":"Nat Rev Cancer"},{"key":"4424_CR66","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338\u201350.","journal-title":"Nat Rev Clin Oncol"},{"key":"4424_CR67","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318.","journal-title":"Nat Rev Cancer"},{"key":"4424_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050470","volume":"8","author":"J Kondo","year":"2019","unstructured":"Kondo J, Inoue M. Application of cancer organoid model for drug screening and personalized therapy. Cells. 2019;8:470.","journal-title":"Cells"},{"key":"4424_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092062","volume":"14","author":"B Medle","year":"2022","unstructured":"Medle B, Sj\u00f6dahl G, Eriksson P, Liedberg F, H\u00f6glund M, Bernardo C. Patient-derived bladder cancer organoid models in tumor biology and drug testing: a systematic review. Cancers (Basel). 2022;14:2062.","journal-title":"Cancers (Basel)"},{"key":"4424_CR70","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","volume":"24","author":"F Weeber","year":"2017","unstructured":"Weeber F, Ooft SN, Dijkstra KK, Voest EE. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol. 2017;24:1092\u2013100.","journal-title":"Cell Chem Biol"},{"key":"4424_CR71","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s12015-024-10714-6","volume":"20","author":"Y Yang","year":"2024","unstructured":"Yang Y, Kong Y, Cui J, Hou Y, Gu Z, Ma C. Advances and applications of cancer organoids in drug screening and personalized medicine. Stem Cell Rev Rep. 2024;20:1213\u201326.","journal-title":"Stem Cell Rev Rep"},{"key":"4424_CR72","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00120-022-01854-z","volume":"61","author":"MK Melzer","year":"2022","unstructured":"Melzer MK, Zehe V, Zengerling F, Wezel F, G\u00fcnes C, Maisch P, et al. Organoids as a milestone on the way to personalized treatment of urothelial carcinoma: a systematic review. Urologie. 2022;61:745\u201352.","journal-title":"Urologie"},{"key":"4424_CR73","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1038\/s41467-020-19058-4","volume":"11","author":"B Schuster","year":"2020","unstructured":"Schuster B, Junkin M, Kashaf SS, Romero-Calvo I, Kirby K, Matthews J, et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020;11:5271.","journal-title":"Nat Commun"},{"issue":"1","key":"4424_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1245\/s10434-021-10829-x","volume":"29","author":"M Flood","year":"2022","unstructured":"Flood M, Narasimhan V, Wilson K, Lim WM, Ramsay R, Michael M, et al. Organoids as a robust preclinical model for precision medicine in colorectal cancer: a systematic review. Ann Surg Oncol. 2022;29(1):47\u201359.","journal-title":"Ann Surg Oncol"},{"key":"4424_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104840","volume":"214","author":"J Ma","year":"2025","unstructured":"Ma J, Li S, Zhang X, Zhao P, Zhao B, Yue J, et al. Lung cancer organoids in translational research: bridging basic science, drug development, and clinical therapeutics. Crit Rev Oncol Hematol. 2025;214:104840.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04424-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:22:42Z","timestamp":1792160562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04424-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4424"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04424-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"340"}}